文献速递肝病消化道肿瘤与早癌

干扰素驱动HCV表观基因组瘢痕形成,病毒清除后仍存在可靶向脆弱性

Interferon drives HCV scarring of the epigenome and creates targetable vulnerabilities following viral clearance.
PubMed 文献 · Hepatology · 2021-12-15

研究探讨慢性HCV感染如何影响表观基因组及病毒清除后变化是否持续。通过全基因组DNA甲基化、四种组蛋白修饰和开放染色质分析,发现HCV深刻影响表观基因组(尤其增强子),多数变化在病毒清除后仍作为「瘢痕」保留,且感染与治愈细胞免疫反应减弱。补充DNA甲基转移酶抑制剂可协同逆转异常甲基化。

要点

  • HCV感染深刻改变表观基因组,尤其增强子区域,且多数变化在病毒清除后仍保留。
  • HCV与干扰素α靶点共享表观遗传靶点,治愈后表观瘢痕可能解释长期HCC风险。
  • DNA甲基转移酶抑制剂5-aza-2'-deoxycytidine与抗病毒方案协同逆转HCV诱导的异常DNA甲基化。

核心结论

  • HCV感染驱动的表观基因组改变在病毒清除后大部分作为瘢痕保留,可能导致治愈患者长期HCC风险升高。

研究设计与样本

  • 研究在永生化肝细胞和Huh7.5 HCC细胞系中,以干扰素α或直接抗病毒药物清除HCV后,进行全基因组DNA甲基化、四种组蛋白修饰和开放染色质分析,并验证于治愈的慢性HCV患者样本。

主要发现

  • HCV感染深刻影响表观基因组,尤其增强子区域。
  • HCV与干扰素α靶点共享表观遗传靶点。
  • 绝大多数HCV诱导的表观遗传变化在病毒清除后仍作为瘢痕保留。
  • 治愈的慢性HCV患者样本中观察到类似发现。
  • 感染和治愈细胞均显示减弱的免疫反应。

关键数值与推荐

  • 补充DNA甲基转移酶抑制剂5-aza-2'-deoxycytidine与干扰素α/直接抗病毒药物方案协同逆转HCV诱导的异常DNA甲基化。

临床怎么用

  • 对于HCV治愈患者,应考虑表观遗传瘢痕导致的长期HCC风险,需持续监测。
  • DNA甲基转移酶抑制剂可能作为辅助策略逆转HCV诱导的表观遗传异常,但需进一步临床验证。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND AND AIMS: Chronic HCV infection is a leading etiologic driver of cirrhosis and ultimately HCC. Of the approximately 71 million individuals chronically infected with HCV, 10%-20% are expected to develop severe liver complications in their lifetime. Epigenetic mechanisms including DNA methylation and histone modifications become profoundly disrupted in disease processes including liver disease. APPROACH AND RESULTS: To understand how HCV infection influences the epigenome and whether these events remain as "scars" following cure of chronic HCV infection, we mapped genome-wide DNA methylation, four key regulatory histone modifications (H3K4me3, H3K4me1, H3K27ac, and H3K27me3), and open chromatin in parental and HCV-infected immortalized hepatocytes and the Huh7.5 HCC cell line, along with DNA methylation and gene-expression analyses following elimination of HCV in these models through treatment with interferon-α (IFN-α) or a direct-acting antiviral (DAA). Our data demonstrate that HCV infection profoundly affects the epigenome (particularly enhancers); HCV shares epigenetic targets with interferon-α targets; and an overwhelming majority of epigenetic changes induced by HCV remain as "scars" on the epigenome following viral cure. Similar findings are observed in primary human patient samples cured of chronic HCV infection. Supplementation of IFN-α/DAA antiviral regimens with DNA methyltransferase inhibitor 5-aza-2'-deoxycytidine synergizes in reverting aberrant DNA methylation induced by HCV. Finally, both HCV-infected and cured cells displayed a blunted immune response, demonstrating a functional effect of epigenetic scarring. CONCLUSIONS: Integration of epigenetic and transcriptional data elucidate key gene deregulation events driven by HCV infection and how this may underpin the long-term elevated risk for HCC in patients cured of HCV due to epigenome scarring.

来源:Hepatology,查看原文。版权归原作者所有。

引用

  1. Hlady RA, Zhao X, El Khoury LY, et al. Interferon drives HCV scarring of the epigenome and creates targetable vulnerabilities following viral clearance. Hepatology. 2021. PMID: 34387871. doi:10.1002/hep.32111

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。